Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | September 17, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date September 17, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,146 |
Reported balance
After 2026-09-17 transaction · row 1
1 source rowRow 1 · 2026-09-17 · Exercise / conversion · Acquired 1,146 · Balance 1,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 2,292 |
Reported balance
After 2026-09-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-17 · Exercise / conversion · Disposed 1,146 · Balance 2,292 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 18, 2026 20:37 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 1,146 | $0.00 | $0.00 |
DisclosureSEC source: 0002083937-26-000005 · form4-09182026_080926.xml · derivative · entry 2 Fuchs Thomas · CIK 0002083937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,292 Underlying: Class A Common Stock · 1,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date. F2 · derivative.expiration_date: The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:37 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 1,146 | $0.00 | $0.00 |
DisclosureSEC source: 0002083937-26-000005 · form4-09182026_080926.xml · nonDerivative · entry 1 Fuchs Thomas · CIK 0002083937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:26 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 4,248 | $0.00 | $0.00 |
DisclosureSEC source: 0002083937-26-000003 · form4-06232026_080631.xml · derivative · entry 1 Fuchs Thomas · CIK 0002083937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,248 Underlying: Class A Common Stock · 4,248 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F2 · derivative.expiration_date: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 20:11 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 3,438 | $0.00 | $0.00 |
DisclosureSEC source: 0002083937-25-000012 · form4-09192025_080930.xml · derivative · entry 1 Fuchs Thomas · CIK 0002083937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,438 Underlying: Class A Common Stock · 3,438 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date. F2 · derivative.expiration_date: The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.